We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. immunomic therapeutics crunchbase. Bard (Becton, Dickinson and Company). Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. All content is posted anonymously by employees working at Immunomic Therapeutics. Immunomic Therapeutics Announces Presentation on Nucleic Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs, Northeastern US Biotechnology Female Founded Companies. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. This employer has not claimed their Employer Profile and is missing out on connecting with our community. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. Phone Number +119196161923. Contact Email info@immunomet.com. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. Curr Opin Immunol. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Melody Carey Harnessing the immune system to achieve deep and durable clinical responses in cancer. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Melissa Kemp Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. ITI Media: ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. ITI Company: Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. In addition, ITI-1001 represents a far more cost-effective approach. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Amy Conrad The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. J Immunol. ITI maintains its headquarters in Rockville, Maryland. ITI Company: With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. ITI Company: ITI-3000 Merkel Cell Carcinoma - pDNA. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. 858-366-3243, Internet Explorer presents a security risk. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. ITI-ID Candidate Multiple infectious diseases. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. Join to follow . We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. The company was founded in 2005 and is based in Lancaster, Pennsylvania. View detailed 028300.KR description & address. In addition, ITI-1001 represents a far more cost-effective approach. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Clin Cancer Res. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. 1K followers 500+ connections. To explore Immunic Therapeutics's full profile, request access. ITI-1001 is an alternative, cell-free approach to treating GBM. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. amy@juniper-point.com The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. J Immunol Res. Those studies had enrolled all comers, and Bristol restricted Checkpoint-548's enrolment to patients carrying the MGMT methylation biomarker in . MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. 2016;2016:4857869. Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. Phone Number +4989208047700. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-.